Defining success in haemophilia care - Are we doing it right?

被引:1
作者
Srivastava, Alok [1 ,2 ]
机构
[1] Christian Med Coll Vellore, Dept Haematol, Ranipet Campus, Vellore, Tamil Nadu, India
[2] Ctr Stem Cell Res, Unit inStem Bengaluru, CMC Campus, Vellore, Tamil Nadu, India
关键词
care; definition; haemophilia; paradigm; success; RECOMBINANT FACTOR-VIII; PROPHYLAXIS; PHASE-3; HETEROGENEITY; DEFINITIONS; ARTHROPATHY; ADOLESCENT; SAFETY; TRIAL; ALPHA;
D O I
10.1111/hae.14958
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Transformational advances have occurred in the management of haemophilia in the last decade leading to much better outcomes. However, a detailed and critical examination of its assessment and reporting show gaps in many aspects. These are discussed in this review. Methods: The relevant literature related to different aspects of management of haemophilia was reviewed to identify gaps which need to be addressed. These include detection and diagnosis of haemophilia, documentation and reporting of joint bleeding, its management and methods of reporting in clinical trials and practice, aspects of personalizing care as well as access to therapeutic products and the need for and organization of comprehensive care. Results: Current diagnostic approaches have more than doubled the identified number of persons with haemophilia (PWH) over the last 25 years but still constitute only similar to 30% of the expected number. Joint bleeding is the primary indicator of disease severity and treatment efficacy, but there is lack of consistency and standardization in the way it is recorded and reported. Its continued use as an efficacy measure of modern treatments which maintain steady state factor levels or equivalence of >5% will lack sensitivity. The treatment of acute haemarthrosis has focussed on haemostasis and pain control, ignoring the role of inflammation in joint damage. Phenotypic heterogeneity of severe haemophilia has recognized clinical and laboratory variations based on haemostasis but not differences in local response to blood in the joint. At the organizational level, IU/capita provides a relevant measure of access to therapeutic products when the detection rate is similar to 100% but is fallaciously low when detection rates are very low. With highly effective modern therapies for haemophilia and nearly no bleeding, the concept of comprehensive care team will need modifications. Conclusion: As haemophilia care advances, a deeper dive is needed into the details of various aspects its management to ensure consistency and contemporary relevance.
引用
收藏
页码:52 / 59
页数:8
相关论文
共 45 条
[1]  
[Anonymous], 2022, WORLD FEDERATION HEM
[2]  
ARONSTAM A, 1984, CLIN LAB HAEMATOL, V6, P9
[3]   Beyond patient benefit: clinical development in hemophilia [J].
Auerswald, Guenter ;
Salek, Silva Zupancic ;
Benson, Gary ;
Elezovic, Ivo ;
Lambert, Thierry ;
Morfini, Massimo ;
Pasi, John ;
Remor, Eduardo ;
Santagostino, Elena ;
Salaj, Peter ;
Ljung, Rolf .
HEMATOLOGY, 2012, 17 (01) :1-8
[4]   Definitions in hemophilia: communication from the SSC of the ISTH [J].
Blanchette, V. S. ;
Key, N. S. ;
Ljung, L. R. ;
Manco-Johnson, M. J. ;
Van Den Berg, H. M. ;
Srivastava, A. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (11) :1935-1939
[5]   HAEMOPHILIC BOY IN SCHOOL [J].
BRITTEN, MI ;
SPOONER, RJD ;
DORMANDY, KM ;
BIGGS, R .
BRITISH MEDICAL JOURNAL, 1966, 2 (5507) :224-&
[6]   Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1-3 [J].
Callaghan, Michael U. ;
Asikanius, Elina ;
Lehle, Michaela ;
Oldenburg, Johannes ;
Mahlangu, Johnny ;
Uguen, Marianne ;
Chebon, Sammy ;
Kruse-Jarres, Rebecca ;
Jimenez-Yuste, Victor ;
Shima, Midori ;
Trask, Peter ;
Kempton, Christine L. ;
Kessler, Craig M. ;
Levy, Gallia G. ;
Peyvandi, Flora .
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2022, 6 (06)
[7]   Factor VIII/factor IX prophylaxis for severe hemophilia [J].
Carcao, Manuel ;
Srivastava, Alok .
SEMINARS IN HEMATOLOGY, 2016, 53 (01) :3-9
[8]   A systematic review of definitions and reporting of bleeding outcome measures in haemophilia [J].
Chai-Adisaksopha, C. ;
Hillis, C. ;
Thabane, L. ;
Iorio, A. .
HAEMOPHILIA, 2015, 21 (06) :731-735
[9]   Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis [J].
Chen, Zhu ;
Bozec, Aline ;
Ramming, Andreas ;
Schett, Georg .
NATURE REVIEWS RHEUMATOLOGY, 2019, 15 (01) :9-17
[10]   Intermediate- dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s [J].
Fischer, Kathelijn ;
Carlsson, Katarina Steen ;
Petrini, Pia ;
Holmstrom, Margareta ;
Ljung, Rolf ;
van den Berg, H. Marijke ;
Berntorp, Erik .
BLOOD, 2013, 122 (07) :1129-1136